Seguridad del levetiracetam como tratamiento adyuvante en la epilepsia: El estudio skate en España

Aim. To continue assessing safety and to evaluate the efficacy of levetiracetam and to assess the optimal dose in community based practice. Patients and methods. Single-arm, open label, multicenter, observational and prospective trial lasting 16-22 weeks. Criteria for inclusion: patients > 16 years experiencing epilepsy with partial seizures taking at least one concomitant antiepileptic drug. The initial dose was 1,000 mg/day, up to the maximal dose of 3,000 mg/day. Safety evaluation was adverse events reporting. Efficacy evaluation were reduction in seizure frequency; QOLIE-IO questionnaire and global evaluation scale of disease severity. Results. Of the 342 subjects, 296 (86.5%) completed the treatment period. 103 subjects (30.1%) experienced at least one adverse event. The most frequently adverse events reported were somnolence (11.7%), dizziness (5.8%) and headache (3.5%). The events were majority of mild to moderate intensity. The median percent reduction in partial seizure frequency per week was 55%. 51.2% of patients experienced a reduction ≥ 50% in partial seizure frequency. Similar results were observed for total seizures. An increase of QOLIE-10 total score was observed (10.2 ± 17.8). A total of 63.5% patients were rated as having moderate or marked improvement in their disease severity. Conclusions. These data confirm and provide additional support of levetiracetam safety and efficacy demonstrated in phase III trials.